Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies
Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis. The recent emergence of novel antidiabetic medications has been demonstrated to exe...
Saved in:
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2025-05-01
|
| Series: | Life |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2075-1729/15/6/843 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849706033692278784 |
|---|---|
| author | Vincenzo Trapanese Annamaria Dagostino Maria Resilde Natale Federica Giofrè Clara Vatalaro Melania Melina Francesca Cosentino Silvia Sergi Felice Imoletti Rocco Spagnuolo Franco Arturi |
| author_facet | Vincenzo Trapanese Annamaria Dagostino Maria Resilde Natale Federica Giofrè Clara Vatalaro Melania Melina Francesca Cosentino Silvia Sergi Felice Imoletti Rocco Spagnuolo Franco Arturi |
| author_sort | Vincenzo Trapanese |
| collection | DOAJ |
| description | Obesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis. The recent emergence of novel antidiabetic medications has been demonstrated to exert a favourable influence on the composition of the intestinal microbiota. Incretin-based therapy exerts a multifaceted influence on the composition of the gut microbiota, leading to alterations in bacterial flora. Of particular significance is the capacity of numerous metabolites produced by the gut microbiota to modulate the activity and hormonal secretion of enteroendocrine cells. This review examines the effects of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/gastric inhibitory polypeptide (GIP) receptor dual agonists on the composition of the gut microbiota in both mice and human subjects. The nature of this interaction is complex and bidirectional. The present study demonstrates the involvement of the incretinic axis in modulating the microbial composition, with the objective of providing novel preventative strategies and potential personalised therapeutic targets for obesity and T2DM. |
| format | Article |
| id | doaj-art-87210be5a10a4ebca3ff89ad14a22945 |
| institution | DOAJ |
| issn | 2075-1729 |
| language | English |
| publishDate | 2025-05-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Life |
| spelling | doaj-art-87210be5a10a4ebca3ff89ad14a229452025-08-20T03:16:18ZengMDPI AGLife2075-17292025-05-0115684310.3390/life15060843Bidirectional Interactions Between the Gut Microbiota and Incretin-Based TherapiesVincenzo Trapanese0Annamaria Dagostino1Maria Resilde Natale2Federica Giofrè3Clara Vatalaro4Melania Melina5Francesca Cosentino6Silvia Sergi7Felice Imoletti8Rocco Spagnuolo9Franco Arturi10Internal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyDepartment of Health Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyInternal Medicine Unit, Department of Medical and Surgical Sciences, “Magna Graecia” University of Catanzaro, 88100 Catanzaro, ItalyObesity, insulin resistance, type 2 diabetes mellitus (T2DM) and metabolic syndrome have been largely correlated to a reduction in bacterial load and diversity, resulting in a condition known as intestinal dysbiosis. The recent emergence of novel antidiabetic medications has been demonstrated to exert a favourable influence on the composition of the intestinal microbiota. Incretin-based therapy exerts a multifaceted influence on the composition of the gut microbiota, leading to alterations in bacterial flora. Of particular significance is the capacity of numerous metabolites produced by the gut microbiota to modulate the activity and hormonal secretion of enteroendocrine cells. This review examines the effects of dipeptidyl peptidase 4 (DPP-4) inhibitors, glucagon-like peptide 1 (GLP-1) receptor agonists and GLP-1/gastric inhibitory polypeptide (GIP) receptor dual agonists on the composition of the gut microbiota in both mice and human subjects. The nature of this interaction is complex and bidirectional. The present study demonstrates the involvement of the incretinic axis in modulating the microbial composition, with the objective of providing novel preventative strategies and potential personalised therapeutic targets for obesity and T2DM.https://www.mdpi.com/2075-1729/15/6/843gut microbiotatype 2 diabetes mellitusobesityincretinDPP-4 inhibitorGLP-1 receptor agonist |
| spellingShingle | Vincenzo Trapanese Annamaria Dagostino Maria Resilde Natale Federica Giofrè Clara Vatalaro Melania Melina Francesca Cosentino Silvia Sergi Felice Imoletti Rocco Spagnuolo Franco Arturi Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies Life gut microbiota type 2 diabetes mellitus obesity incretin DPP-4 inhibitor GLP-1 receptor agonist |
| title | Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies |
| title_full | Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies |
| title_fullStr | Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies |
| title_full_unstemmed | Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies |
| title_short | Bidirectional Interactions Between the Gut Microbiota and Incretin-Based Therapies |
| title_sort | bidirectional interactions between the gut microbiota and incretin based therapies |
| topic | gut microbiota type 2 diabetes mellitus obesity incretin DPP-4 inhibitor GLP-1 receptor agonist |
| url | https://www.mdpi.com/2075-1729/15/6/843 |
| work_keys_str_mv | AT vincenzotrapanese bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT annamariadagostino bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT mariaresildenatale bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT federicagiofre bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT claravatalaro bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT melaniamelina bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT francescacosentino bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT silviasergi bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT feliceimoletti bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT roccospagnuolo bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies AT francoarturi bidirectionalinteractionsbetweenthegutmicrobiotaandincretinbasedtherapies |